Why Gilead Sciences Stock Slipped Today
Prominent pharmaceutical company Gilead Sciences (NASDAQ: GILD) wasn't prominent in the minds of investors on Monday. Following media reports that a key federal agency was contemplating a move that might affect its business, the market collectively sold out of Gilead's stock to leave it with an almost 3% loss on the day. That decline was in contrast to the S 500's (SNPINDEX: ^GSPC) slight (0.02%) rise.
Those reports derived from a Wall Street Journal article published last Friday evening. Citing unidentified "people familiar with the matter," the financial newspaper wrote that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. aims to dismiss all current members of the U.S. Preventive Services Task Force (USPSTF), a panel that advises HHS on such healthcare products.
Image source: Getty Images.
Source Fool.com
